Abstract 832P
Background
Treating pediatric acute B-cell lymphoblastic leukemia (pB-ALL) who experience central nervous system relapses (CNSR) is challenging and often results in high mortality rates. The aim of this study was to develop and validate a predictive model for CNSR in pB-ALL, allowing for early identification and assessment.
Methods
1495 patients of pB-ALL patients from the TARGET database were randomly assigned to a training cohort of 1079 patients and an internal validation cohort of 416 patients. Multi-variable COX regression analysis was applied to construct the model using the training cohort. The validation cohorts comprised of an internal validation cohort and an external validation cohort consisting of Chinese patients. The analysis was conducted using consistency index (C-index), AUROC, Kaplan-Meier curves, calibration curve, and decision curve analysis to evaluate this model.
Results
The prediction model for CNSR in pB-ALL, named CLOMB, was constructed using indicators selected from the training cohort. The model had a C-index of 0.748 and was found to be highly accurate in predicting CNSRs in both the training and validation cohorts, as determined by AUROC measures. A statistically significant difference in event-free survival was observed between pB-ALL patients divided into CNSR high-risk and low-risk groups using the CLOMB calculated risk score of 0.76 as a cut-off value. In the external validation cohort, CLOMB had an AUROC of 0.590, which was significantly higher than MRD on days 19 and days 46.
Conclusions
The newly developed predictive model, CLOMB, has shown strong power and utility in CNS relapse prediction and risk stratification, which may help modify treatment options in clinical routine.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
National Natural Science Foundation of China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
697P - The Empower Pathway overview: An innovative approach to delivering personalised care for testicular cancer survivors
Presenter: Robert Holwell
Session: Poster session 09
698P - Outcomes of patients with testicular germ cell tumors in Latin-America
Presenter: Saul Campos Gomez
Session: Poster session 09
699P - Prospective COTRIMS (COlogne Trial of Retroperitoneal Lymphadectomy in Metastastic Seminoma) trial: Three year update
Presenter: Axel Heidenreich
Session: Poster session 09
701P - Multicenter analysis of first-line (1L) regimens (BEP vs VIP) in patients (pts) with non-seminomatous germ cell tumors (NSGCTs) who subsequently underwent high-dose chemotherapy (HDCT)
Presenter: Hedyeh Ebrahimi
Session: Poster session 09
702P - Survival and related factors in testicular non-seminomatous patients undergoing high-dose chemotherapy and autologous stem cell transplantation: Experience of Turkey's highest volume transplantation center
Presenter: Musa Baris Aykan
Session: Poster session 09
703P - Survival of Hispanic germ cell tumor patients at a single academic institution vs. SEER
Presenter: Adam Kolawa
Session: Poster session 09
704P - Characteristics and palliative management of patients with cisplatin-refractory germ cell tumours: A Global Germ Cell Cancer Collaborative Group (G3) retrospective registry study
Presenter: Christoph Oing
Session: Poster session 09
705P - Subsequent malignant neoplasms (SMN) in patients with germ cell tumor of the testis (TGCT): Implications on a genetic vs stem cell origin of cancers
Presenter: Sruthi Vellanki
Session: Poster session 09
706P - Stereotactic radiosurgery (SRS) in brain metastases (BMs) from non-seminomatous germ cell tumours (NSCGTs)
Presenter: Deep Chakrabarti
Session: Poster session 09